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Rapport de synthèse 
La concentration d'IGFBP-3 dans le liquide amniotique, un indicateur précoce de la 
croissance intra-utérine 
Introduction : 
La croissance fœtale intra-utérine dépend d'un grand nombre de facteurs maternels, 
placentaires et fœtaux. Une inadéquation d'un ou plusieurs de ces facteurs peut induire un 
retard de croissance intra-utérin (RCIU) ou au contraire une macrosomie. Les principales 
causes de RCIU comprennent les infections maternelles, l'éclampsie, les cardio-
vasculopathies maternelles, la toxicomanie, les malformations fœtales et les insuffisances 
placentaires. Les facteurs endocriniens constituent un petit pourcentage des causes de RCIU, 
mais méritent que l'on s'y intéresse de plus près. Les facteurs hormonaux les plus importants 
pour la croissance fœtale sont l'insuline et les insuline-like growth factors (IGFs) et non 
l'hormone de croissance (GH) qui joue un rôle majeur dans la croissance postnatale. 
Notre attention s'est portée sur IGF-1 qui joue un rôle important dans la croissance intra-
utérine. Sa biodisponibilité dépend de plusieurs protéines plasmatiques, les IGF-binding 
proteins (IGFBP 1 à 9). IGFBP-3 est la principale de ces IGFBPs, autant d'un point de vue 
quantitatif que fonctionnel. 
Nous avons cherché à déterminer si les concentrations d'IGF-1 et d'IGFBP-3 dans le liquide 
amniotique au début du deuxième trimestre étaient prédictives de la croissance intra-utérine. 
Les gènes codant pour IGF-1 et IGFBP-3 contenant certaines séquences polymorphiques, 
nous avons également étudié leur influence sur la croissance foetale. 
L'analyse du liquide amniotique présente l'avantage de pouvoir être effectuée dès la 14ème 
semaine d'aménorrhée alors que la biométrie foetale échographique ne permet pas à ce stade 
de déceler des anomalies de la croissance intra-utérine. 
Méthode: 
Nous avons analysé des échantillons de liquide amniotique prélevés entre la 14ème et la 18ème 
semaine de grossesse chez 196 patientes. Les concentrations d'IGF-1 et d'IGFBP-3 ont été 
dosées par ELISA, les polymorphismes analysés par PCR. Ces résultats ont été ensuite 
analysés en fonction du poids de naissance des nouveaux-nés, répartis en trois groupes : 
normal pour l'âge gestationnel (AGA), petit pour l'âge gestationnel (SGA) et grand pour l'âge 
gestationnel (LGA). 
Résultats: 
Les concentrations d'IGFBP3 dans le liquide amniotique sont significativement plus élevées 
(p = 0.030) dans le groupe SGA par rapport au groupe AGA, d'autant plus quand les taux sont 
ajustés en fonction de paramètres tels que l'âge gestationnel lors de l'amniocentèse 
(ANCOVA analysis: p = 0.009). La distribution du polymorphisme VNTR (variable number 
of tandem repeat) dans la région promotrice d'IGF-1 au sein du groupe SGA est 
significativement différente de celle du groupe AGA (p = 0.029). En effet, la fréquence de 
l'association allélique 19CA/20CA est diminuée dans le groupe SGA. 
Nous n'avons pas identifié de différence de distribution des séquences polymorphiques 
d' IGFBP-3 entre les différents groupes. 
Conclusion : 
Une concentration élevée d'IGFBP-3 dans le liquide amniotique au début du deuxième 
trimestre est associée à un risque plus élevé de retard de croissance alors que l'association 
allélique 19CA/20CA dans la région polymorphique JGF-1 VNTR est un facteur protecteur. 
European journal of Obstetrics & Gynecology and Reproductive Biofogy 144 (2009) 15-20 
Contents lists available at ScienceDirect 
European journal of Obstetrics & Gynecology and 
Reproductive Biology 
journal liomepage: www.elsevi~r.com/locate/ejogrb 
Amniotic fluid insulin-like growth factor binding protein 3 concentration 
as early indicator of fetal growth restriction 
Geraldine Murisier-Petetin, Sandrine Gremlich, Francoise Damnon, Danielle Reymondin, 
Patrick Hohlfeld, Stefan Gerber* 
Department of Gynecology, Obstetrics and Medical Genetics, CHUV Hospital, Av. Pierre-Declœr 2, 1011 Lausanne, Switzerland 
ARTICLE INFO 
Article history: 
Received 31 july 2007 
Received in revised form 23 September 2008 
Accepted 13 January 2009 
Keywords: 
lnsulin-like growth factor 
Fetal growth 
Polymorphism 
Amniotic fluid 
1. Introduction 
ABSTRACT 
Objective: Insulin-like growth factor-! (IGF-1) is an important regulator of fetal growth and its 
pioavailability depends on insulin-like growth factor binding proteins (IGFBPs). Genes coding for IGF-1 
and lGFBP3 are polymorphie. We hypothesized that either amniotic fluid protein concentration at the 
beginning of the second trimester or genotype of one of these two genes could be predictive of abnormal 
fetal growth. 
Study design: Amniotic fluid samples (14-18 weeks of pregnancy) from 123 patients with appropriate 
for gestational age (AGA) fetuses, 39 patients with small for gestational age (SGA) fetuses and 34 patients 
with large for gestational age (LGA) were.analyzed. Protein concentrations were evaluated by ELISA and 
gene polymorphisms by PCR. 
Resu/ts: Amniotic fluid IGFBP3 concentrations were significantly higher in SGA compared to AGA group 
(P = 0.030), and this was even more significant when adjusted to gestational age at the time of 
amniocentesis and other covariates (ANCOVA analysis: P = 0.009). Genotypic distribution of IGF-1 
variable. number of tandem repeats (VNTR) polymorphism was significantly different in SGA compared 
to AGA group (P = 0.029). 19CA/20CA genotype frequency was threefold decreased in SGA compared to 
AGA group and the risk of SGA occurrence of this genotype was decreased accordingly: OR= 0.289, 
95%CI = 0.1-0.9, P = 0.032. Genotype distribution of IGFBP3(A-202C) polymorphism was similar in al! 
three groups. · 
Conclusions: High lGFBP3 concentrations in amniotic fluid at the beginning of the second trimester are 
associated with increased risks of SGA while 19CA/20CA genotype at IGF-1 VNTR polymorphism is 
associated with reduced risks of SGA. Neither IGFBP3 concentrations, nor IGF-I/IGFBP3 polymorphisms 
are associated with modified risks of LGA. 
© 2009 Elsevier lreland Ltd. Ali rights reserved. 
lntrauterine growth is a complex process depending on 
maternai, fetal and placenta! factors, but also on environmental 
conditions. lt is principally controlled by growth hormone-
independent insulin-like growth factor (IGF) production until just 
before birth [1-4]. 
increase IGF half-life, contrai IGF transport, regulate JGF-IGF 
receptor interaction and also prevent cell growth overstimulation 
[5]. But IGFBPs also act through their own receptors, inducing 
pathways sometimes opposed to IGF actions such as cellular 
growth inhibition or apoptosis stimulation [2,5]. 
Previous studies in mice have shown that IGF-1 KO resulted in 
intrauterine growth retardation and post-weaning growth defect 
[10,11 ], and ALS KO in a modestreduction in postnatal growth [12]. There are two forms oflGF, IGF-1 and -Il, in which none is.able to 
cross the placenta! barrier. Animal experiments have shown that 
IGF-1 was principally involved in fetal and postnatal growth/ 
development and IGF-11 in placenta! development [5-8]. 75-80% of 
IGF is present as a complex with ALS (acid-labile subunit) and 
insulin-Jike growth factor binding protein 3 (IGFBP3 ), 20-25% is 
as.sociated with other IGFBPs, and Jess than 1% is free [9]. IGFBPs 
• Corresponding author. Tel:: +41 21 314 33 60; fax: +41 21 314 35 25. 
E-mail address: Stefan.Gerber@chuv.hospvd.ch (S. Gerber). 
0301-2115/$ - see front matter © 2009 Elsevier Ireland Ltd. Ali rights reserved. 
doi: 10.1016/j.ejogrb.2009.01.004 
No clear association between birth weight and IGF family 
members levels in amniotic fluid (AF) at the beginning of the 
second trimester could be demonstrated [4,13,14]. although Tisi 
et al. reported a significant association between AF IGFBP3 Jevel 
and newborn birth weight in macrosomes [15]. 
Genes coding for IGF-1 and IGFBP3 are polymorphie. IGF-1 gene 
was shown to · contain a Variable Number of Tandem Repeats 
(VNTR) in the promoter region and IGFBP3 gene a single nucleotide 
polymorphism (SNP) (A_, C) at position -202 in the promoter 
region. 
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If some controversy exists on the association between IGF-1 
VNTR and JGF-1 s'erum values, most studies showed a significant 
reduction of IGF-1 concentrations in non-carriers of the most 
common allele, 19CA [ 16-20]. IGFBP3 SNP was shown to correlate 
with adult IGFBP3 serum concentrations, the mutated C allele 
being associated with decreased circulating concentrations 
[21,22]. 
Most of the studies looking at the fetal somatotropic axis used 
cord blood at delivery as starting material. In this study, we 
analyzed AF sampi es at the beginning of the second trimester and 
focused on IGFBP3 protein quantification and IGF-I/IGFBP3 poly-
morphisms analysis in three different groups: SGA, AGA, and LGA. 
We hypothesized that one of these biochemical/genetic markers 
could be predictive of abnormal fetal growth although an increase 
in IGFBP3 levels could lead both to an increase in IGF-1 stability 
(stimulatory effect) and an increase in sequestration of the growth 
factor (inhibitory effect), depending on the context. 
2. Materials and methods 
2.1. Subjects 
AF samples were obtained from women with singleton 
pregnancies admitted for amniocentesis at the Lausanne Uni-
versity Hospital in 2003-2004. Amniocentesis indications were 
materna! anxiety, materna! age >35 years, pathological T21 
screening tests (predictive value > 1 :380) or family history of 
chromosomal abnormality. 
Inclusion criteria were amniocentesis at 14-18 weeks of 
gestation and delivery after 37 weeks. Exclusion criteria were 
materna! HIV+, HBV+, systemic disease or primo-infection (cyto-
megalovirus, toxoplasmosis, rubella, syphilis and varicella), and 
fetal malformation or chromosomal abnormality. 
SGA was defined by ultrasonographic follow-up during the 
second/third trimes ter showing a biometry < 10th percentile and a 
newborn birth weight < 10th percentile [23], AGÀ by a newborn 
birth weight between 1 Oth and 90th percentile and LGA by a 
newborn birth weight >90th percentile. Gestational age was based 
Table 1 
exclusivèly on first trimester ultrasound (8-1 O weeks of gestation). 
378 samples were obtained. Out of them, the first 123 AGA only 
were analyzed, plus ail SGA (39 samples) and ail LGA (34 samples), 
to obtain the 180 samples necessary for our analysis following our 
sample size calculation. Three SGA cases with uterine pathological 
Doppler were excluded, in order to have a homogeneous SGA 
population. 
This protocol was approved by !RB of Biology/Medicine Faculty 
of Lausanne University. Ali patients were informed and asked for 
their consent before the study. Ali maternal/fetal data were 
prospectively recorded and assigned a number to ensure patient 
anonymity. 
2.2. Samples 
One milliliter AF was centrifuged 5 min at 2500 rpm. Super-
natant was stored at -80 ac and cell pellet used for DNA extraction 
by adding240 µ,J NID (SO mM KCL, 10 mMTris-HCl pH 8.3, 2.5 mM 
MgClz, 1% Brij 35) and 10 µJ proteinase K (5 mg/ml). Sample was 
incubated 1 h at 56 ac. 10 min at 95 °C, and stored at -80 °C. 
Supernatant was used for protein quantification and pellet for 
polymorphism studies. 
2.3. IGFBP3 quantification 
IGFBP3 AF concentrations were measured by ELISA (Biosource 
Europe SA, Belgium). Detection limit was 10.5 ng/ml, and there 
was no cross-reactivity for IGF-1, IGFBP1 and IGFBP2. 
2.4. IGF-I VNTR polymorphism 
Polymorphie region (-841 in the promoter) was amplified by 
PCR with primers: 5'-GCTTCTATTGCTAGCCAGCTGGTGT-FAM-3' 
and 5'-GGGCAAACAATTTTCCTGT-3'. Reaction was carried out in 
25 µ!: 10 µ,! DNA, 2.5 µ,! 10x PCR buffer, 0.5 µl 10 mM dNTPs, 
0.15 µl Taq DNA polymerase (Roche), 0.5 µl each primer (50 µM) 
and 1.5 µl DMSO. Amplification was: 2 min at 94 °C, 35 cycles of 
1 min at 94 °(, 30 s at 62 °C and 45 s at 72 °C, and 7 min at 72 °C. 
Maternai, newborn and amniotic fluid characteristics in SGA, AGA and LGA patient groups. 
SGA (11 = 39) AGA(11=123) l.GA (Il= 34) 
Mot/Jer 
Age (ycars) 35.0 ± 4.8 (21-43) 35.7 J: 4.3 (23-44) 35.7 ± 5.0 (24-45) 
Gravidily 2.0 :1: 0.9 ( 1-4)' 2.6 J: 1.5 (1-8) 2.8 ± 1.9 (1-10) 
l'arity 0,6 ± 0.8 (0-3)' 1.0 J: 0.9 (0-4) 1.4:!:1.1 (0-5)' 
llMI (kg/m2 ) 23.2 ± 3.5 23.5 ± 3.8 24.9 ± 3.9 
Ethnie origin: caucasian (%) 87.2 86.8 88.2 
Smoking(%) 5.3 5.0 2.9 
Plll/GD (%) 10.5 8.4 2.9 
Newbom 
Birth weight (BW) (g) 2526 ± 257' 3349 ±313 4075 ± 249° 
Placenta weight (l'W) (g) 438 ± 91° 607 ± 116 697 ± 115' 
l'W/BWr,1tio 0.17 0.18 0.17 
GA at time of delivery (weeks) 38.9 ± 1.2 39.3 :!: 1.2 39.0 :!: 1.2 
Melhocl of delivery ratio {% CS) 43.6' 21.1 32.4 
Gencler (%male) 28.2' 52.0 79.41 
A11111iotic fl11id 
GA at time of amnioccntesls (weeks) 16.5 ± 0.8 16.5 ± 0.8 16.5±0.7 
IGFBP3 (ng/ml) 6359 ± 384 5384 :i: 219 5015 ± 288 
lnclepenclent Sample Hest P= 0.030 NS 
ANCOVA analysis'' P= 0,009 NS 
PIH = pregnancy-induced hypertension; GD= gestational diabetes; GA= gestational age; CS= caesarean section; NS = not significant. Data are presented as mean ± s .. d. 
except for IGFBP3 values (mean ± s.e.m.). Minima-maxima are indicated in brackets. 
' P < 0.05 versus AGA by independent Sample. t-test. 
1 P < 0.05 versus AGA by Mann-Whitney U-test. 
t. P < 0.05 versus AGA by Fisher's exact test. 
a Covariates include gestational age at the time of amniocentesis, maternai BMI, gravidity, parity, ethnie origin, age, smoking and PIH/GD status, and fetal gender. 
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PCR product size was determined by Genescan analysis 
(Microsynth, Ba,lgach, Switzerland). Product size correlated with 
CA repeat number. Ten samples were sequenced to check 
Genescan analysis accuracy. 
2.5. IGFBP3(A-202C) polymorphism 
Polymorphie region (-202 in the promoter) was amplified by 
PCR with primers: 5'-CCGAGAGCGGAAGGGGTAAG-3' and 5'-
CCCGTGCTTCGCCCTGAGCA-3'. Reaction was carried out as above 
but amplification was: 2 min at 94 ac, 35 cycles of30 s at 94 ac, 30 s 
at 65 ac and 15 s at 72 ac, and 7 miri at 72 ac. Avi li restriction 
enzyme (Roche) was µsed for PCR digestion (1 h at 37 ac) and DNA 
fragments were analyzed on 2% agarose gels. Non-mutated allele 
yielded a 244 bp fragment, and mutated allele two fragments of 
164 and 80 bp. 
2.6. Statistical analyses 
Results are expressed as mean ±standard .deviation (s.d.) for 
patient characteristics and mean ±standard error of means (s.e.m.) 
for IGFBP3 concentrations. Stµdent's t, Mann-Whitney U, Kruskall-
Wallis H, Fisher's exact or Chi2 tests were used for maternal/newborn 
characteristics ( depending on the type of variable and of variance 
between groups). ANCOVA analysis was used for IGFBP3 concentra-
tions, using gestational age at the time of amniocentesis, maternai 
BMI, gravidity, parity, ethnie origin, age, smoking and PIH/GD status 
and fetal gender as covariates. Binary logistic regression analysis was 
used to evaluate genotype results versus other parameters potentially 
influencing fetal growth. Receiver ·operating characteristic curve 
analysis was used to evaluate correlation between IGFBP3 concen-
tration and fetal growth phenotype. Ali statistical analyses were 
performed using SPSS 14.0 software (SPSS !ne., Chicago, IL) and 
differences were significant when P < 0.05. 
3. Results 
3.1. Subjects 
A total of 196 patients were included in this study, which were 
39 SGA, 123 AGA and 34 LGA. Maternai characteristics were 
comparable in ail three groups, except gravidity and parity, which 
were lower in SGA and higher in LGA compared to AGA group 
(P < 0.05 versus AGA group, except for gravidity in LGA group) 
(Table 1 ). For newborn chat'acteristics, rate of caesarean section 
was significantly higher in SGA than in AGA group (P = 0.006), 
probably due to patient management in case of fetal growth 
restriction (Table 1 ). Birth weights were of course significantly 
different in the three groups, with rnean values of 2526 ± 257 gin 
SGA, 3349 ± 313 gin AGA and 4075 ± 249 gin LGA group (P < 0.001 
versus AGA group in bath cases). Placenta weights were also 
significantly higher in LGA (697 ± 115 g) and lower in SGA 
( 438 ± 91 g) compared to AGA group (607 ± 116 g) (P = 0.002 and 
P < 0.001, respectively), while placenta to birth weight ratio was not 
significantly modified (O. 17 in SGA and LGA, versus 0.18 in AGA group, 
NS in bath cases). Finally, there was a 1.5-fold higher percentage of 
males in LGA and a 1.8-fold lower percentage of males in SGA, 
compared to AGA group (P = 0.004 and 0.010, respectively). 
3.2. IGFBP3 concentration 
IGFBP3 AF concentrations were significantly higher in SGA than 
in AGA group (6359 ± 384 versus 5384 ± 219 ng/ml, P = 0.030), 
white there was no statistical difference between AGA and LGA 
groups (5384 ± 219 ng/ml versus 5015 ± 288 ng/ml, respectively) 
(Fig. 1A, Table 1 ). However, IGFBP3 AF concentration also increased 
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Fig. 1. (A) Amniotic fluid IGFBP3 concentrations are higher in SGA than in AGA 
group. (B) Amniotic fluid IGFBP3 concentrations proportionally increase with 
gestational age. Restilts are expressed as mean ± s.e.m. AF IGFBP3 concentrations 
were measured by ELISA. Statistical analysis were done by independent Sample t-test 
and ANCOVA analysis and results were considered significant when P < 0.05. 'P < 0.05 
vs. AGA group. 
with gestational age (Fig. 1B) and when gestational age and other 
factors such as maternai BMI, gravidity, parity, ethnie origin, age, 
smoking and PIH/GD status, and fetal gender were taken into account, 
the difference between SGA and AGA values was even more 
significant (ANCOVA analysis: P = 0.009) (Table 1 ). A receiver 
operating characteristic curve analysis was performed on a sub-
group of patients (16-17 weeks of gestation) to minimize the effect of 
gestational age but to not significantly affect the size of the sample. 
Area under the curve (AUC) indicated a fair predictive value of!GFBP3 
AF concentrations for SGA (AUC = 0.7, 95%Cl = 0.6-0.8, P = 0.005), and 
the cut-off value giving the best sensitivity (70%) and specificity (61%) 
was 5445 ng/ml (data not shown). 
3.3. IGF-I VNTR polymorphism 
IGF-1 VNTR allele distribution was wide, varying front 16 to 22 
CA repeats, 19 CA being the most common allele (Table 2). Allele 
distribution was not statistically modified in SGA, compared to 
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Table 2. 
Amniotic fluid 1GFBP3 concentration by genotype, and IGF-l/1GFBP3 polymorphisms results in SGA, AGA and LGA patient groups. 
AF concentriltion Phenotype groups 
IGFBP3 SGA AGA LGA 
ng/ml l'' Il(%) Oclcls rutio (95%CI) l' Il(%) Il(%) Odds riltio (95%Cl) l' 
/GF-1 VNTll 
Gcnotypc 
19CA/19CA 5344 ± 212 19 (48.7) 1.000 55 (44.7) 16 (47.1) 1.000 
19CA/20CA 5641±312 NS 4 (10.3) 0.289 (0.1-0.9) 0,032 40 (32.5) 7 (20.6) 0,602 (0.2-1.6) NS 
19CA/21CA 7080 :I; 939 0.050 4 (10.3) 1.053 (0.3-3.7) NS 11 (8.9) 3 (8.8) 0,938 (0.2-3.8) NS 
18CAJ19CA 4815 ± 561 NS 4 (10.3) 2.895 (0.7-12.7) NS 4 (3.3) 1 (2.9) 0.859 (0.1-8.2) NS 
Other 5047 :1: 388 NS 8 (20.5) 1.781 (0.6-5.0) NS 13 (10.6) 7 (20.6) 1.841 (0.6-5.4) NS 
Allelc 
16CA 1 (1.3) NA 0 (0.0) 0 (O.O) NA 
17CA 0 (0.0) NA 4 (1.6) 0 (0.0) NA 
18CA 6 (7.7) 3.288 (1.0-10.6) NS 6 (2.4) 2 (2.9) 1.213 ( 0.2-6.2) NS 
19CA 52 (66.7) 1.000 171 (69.5) 47 (69.1) 1.000 
20CA 11 (14.1) 0.754 (0.4-1.6) NS 48 (19.5) 13 (19.1) 0.985 (0.5-2.0) NS 
21CA 7 (9,0) 1.771 (0.7-4.7) NS 13,(5.3) 3 (4.4) 0,840 (0.2-3. 1) NS 
22CA 1 (1.3) 0.822 (0,1-7.5) NS 4 (1.6) 3 (4,4) 2.729 (0.6-i2.6) NS 
/Gflil'3 SNI' 
Gcnolype 
AA 5237 ± 2G5 12 (31.6) 1.000 32 (26.0) 7 (21.2) 1.000 
AC 5667 :1: 230 NS 18 (47.4) 0.706 (0.3-1.6) NS 68 (55.3) 21 (63.6) 1.412 (0.5-3,7) NS 
cc 5523 ± 168 NS 8 (21.1) 0.928 {0,3-2.6) NS 23 (18.7) 5 (15.2) 0.9fl4 (0.3-3.5) NS 
Allclc 
A 42 (55.3) 1.000 132 (53.7) 35 (53.0) 1.000 
c 34 (44.7) 0.937 (0.6-1.G) NS 114 (46.3) 31 (47.0) 1.026 (0.6-1.8) · NS 
NA= not applicable; NS = not significant; 'ANCOVA analysis with covariates including gestational age at the time of amniocentesis.'maternal BMI, gravidity, parity, ethnie 
origin, age, smoking and PlH/GD status, and fetal gender; PIH = pregnancy-induced hypertension; GD= gestational diabetes; GA= gestational age; NS = not significant. 
AGA group, but a statistically significant difference was observed 
between SGA and AGA groups at the genotype level (P = 0.029). 
19CA/20CA genotype was three-fold less frequent in SGA than in 
AGA group, which corresponded to a decreased risk of SGA 
occurrence compared to the most common 19CA/19CA genotype: 
OR= 0.289, 95%CI =O. 1-0:9, P = 0.032. No statistical difference was 
observed in allele or genotype distribution between LGA and AGA 
groups. 
Global analysis of the different factors potentially responsible 
for SGA phenotype indicated that JGF-1 19CA/20CA genotype was a 
statistically significant component of the equation, as was 
primiparity (P = 0.045 and 0.034, respectively) (Table 3). 
Table 3 
Logis tic regression analysis of the contribution of suspected/known risk factors to 
the final SGA phenotype. 
Mol/1er 
Ethnie origin 
1'11-1/GD 
Smoking 
l'rimiparity 
Age 
BMI (kg/1112) 
New/JOrn 
IGF-1 polymorphism: 
19CA/20CA 
19CA/21CA 
18CA/19CA 
Othcr 
Constant 
l'hcnotype (SGA) 
Exp(B) = Odds ratio 
0.969 
1.293 
1.255 
2.362 
0.954 
0,992 
0.290 
0.794 
2.164 
1.495 
1.547 
95%CI 
0.3-3. 1 
0.3-5.6 
0.2-9.6 
1.1-5.2 
0.9-1.0 
0.9-1.I 
0.1-1.0 
0.2-3.0 
0.4-11.6 
0.5-4.4 
f' 
NS 
NS 
NS 
0.034 
NS 
NS 
NS 
0,045 
NS 
NS 
NS 
NS 
JGFBP3 AF concentrations were statistically higher in IGF-1 
VNTR genotype 19CA/21 CA, compared to 19CA homozygotes 
(Table 2). 
3.4. IGFBP3(A-202C) polymorphism 
In AGA group, A and C alleles were present with almost the 
same frequency (53.7 and 46.3%, respectively) (Table 2). AC was 
the predominant genotype (55.3% of the population) and no 
significant differences in allele or genotype distribution were 
observed between SGA or LGA, and AGA groups. 
No difference in IGFBP3 AF concentrations was observed 
between JGFBP3 SNP genotypes (Table 2). 
4. Comment 
Most of the studies Iooking at the fetal somatotropic axis have 
studied cord blood at delivery. Here, we focused on IGFBP3 
concentrations at the beginning of the second trimester and 
studied fetal genetic profiles of IGF-I and IGFBP3 gene polymorph-
isms in search of predictive markers of abnormal fetal growth. 
Maternai and fetal characteristics showed several features 
already reported, like a gravidity/parity higher in LGA and lower in 
SGA and a newborn male gender prevalence higher in LGA [24,25 ], 
or even a placenta weight and placenta to newborn birth weight 
ratio smaJler in SGA (significant for placenta weight only in our 
sample collective) [26]. 
AF IGFBP3 concentrations in SGA group were higher than in 
AGA or even in LGA groups, no matter what the gestational age. 
Spearman's correlation analysis indicated a highly significant 
relationship between JGFBP3 concentrations and newborn per-
centile: <5th (severe SGA) (6403 ± 559 ng/ml), 5th-10th (light 
SGA) (6313 ± 539 ng/ml), 10th-50th ("small" AGA) (5654 ± 294 ng/ 
ml), 50th-90th ("large" AGA) (5151±319 ng/ml), >90th percentile 
(LGA) (5015 ± 288 ng/ml) (P = 0.001) (data not shown) .. On the 
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contrary, Tisi et al. reported a positive correlation between AF IGFBP3 
concentrations and newborn birth weight in macrosomes [15]. This 
discrepancy could be due to the degree of ethnie heterogeneity of 
their population (69% Caucasian versus 87% in ours). But it could also 
be due to the fact that the positive correlation reported was only 
found in LGA, 'whereas their mean IGFBP3 values did not differ 
between SGA, AGA and LGA [15]. 
The overall allele distribution of lGF-1 VNTR found in our study 
was similar to previous reports (70% 19CA, 20% 20CA, 5% 21 CA and 
2% 18CA repeats) [18,19]. and it was in Hardy-Weinberg 
equilibrium. Only one genotype, 19CA/20CA, was associated to a 
modified (reduced) risk of SGA occurrence. Vaessen et al. had 
previously described an associ.ation between the absence of 19CA 
in the fetal genome and a reduction in birth .weight compared to 
19CA homozygotes [27]. We also found a threefold increase in 
genotypes without 19CA in SGA compared to AGA group (15.4% 
versus 5.7%), but the risk of SGA occurrence linked with this 
absence was not statistically modified compared to the presence of 
one 19CA (OR= 3.731, 95%CI = 1.1-12.8, P = 0.066) or compared to 
19CA homozygotes (OR=2.481, 95%Cl=0.7-8.3, P=0.183). This 
difference could be due to dur sample size, as only 6-7 individuals 
were devoid of 19CA allele in SGA and AGA groups, but it could also 
be due to the fact that the reduction in birth weight reported did 
not take into account the birth weight percentile [27]. 
Genotype distribution of IGFBP3 SNP was similar to previous 
studies that showed a marked predominance of AC genotype (54%) 
[21,22]. and it followed the Hardy...:Weinberg law. M genotype 
was shown to correlate with higher IGFBP3 circulating concentra-
tions than AC and finally CC genotype in adults, although 
differences were low [21,22 ]. In our study, no association between 
1GFBP3 genotype and AF concentration was observed, even when 
the gestational age at the time of amniocentesis and the other 
maternal/fetal characteristics were controlled for (ANCOVA 
analysis: P = 0.337). This could be due to the fact that factors 
regulating IGFBP3 gene expression during intrauterine life are 
different from those expressed at adulthood, or to the fact that AF 
concentrations are not proportional to cirçulating concentrations. 
Morimoto et al. previously reported a cross-association 
between the absence of 19CA allele in IGF-1 VNTR and higher 
IGFBP3 plasma concentrations [28] that we did not find in our 
study, no matter what the gestational age at the time of 
amniocentesis or the other maternal/fetal parameters used as 
covariates (ANCOVA analysis: P= 0.882). However, in Morimoto 
et al. study, differences between 19CA homozygotes and the other 
genotypes were only of 5% [28], and again, AF concentrations might 
simply not reflect circulating concentrations. 
Mause animal studies have shown that ubiquitous transgenic 
expression of 1GFBP3 resulted in higher 1GFBP3 and lGF-1 
circulating concentrations and a modest reduction in size of the 
transgenic pups (10%) which persisted in early postnatal life [29]. 
On the other hand, IGFBP3 single KO showed no growth phenotype, 
but 1GFBP3-5 triple KO exhibited the prenatal growth defect 
observed in 1GFBP4 single KO, plus a postnatal growth defect 
significant from day 20 and thereafter. This was associated with a 
decrease in lGF-1 circulating concentrations and bioactivity [30]. lt 
is clear that the presence of multiple rnembers in the IGFBPs fa mil y 
allows comp'ensation mechanisms between members. Moreover, 
lGFBPs have bath inhibitory and stimulatory effects on IG~-1 action, 
depending on the situation. In our study, we found that higher 
IGFBP3 AF concentrations were associated with lower birth weight 
percentile, coherent with the transgenic animal profile and with 
the fact that AF concentrations are proportional to circulating 
concentrations. 
In summary, we have shown that IGFBP3 AF concentration at 
14-18 weeks of pregnancy negatively correlated with newborn 
percentile. We also have shown that a particular IGF-l VNTR 
genotype, 19CA/20CA, was associated with a reduced risk of SGA 
occurrence to the same extent that primiparity was associated 
with an increased risk of SGA occurrence. These results taken 
together could help predict abnormal fetal growth in early 
pregnancy. 
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